Just another fat-figure they can add to the financials....try marketing it...I bet Favrille tried already.
Through May of 2008, pre-merger Favrille had spent more than $140 million on the creation and development of intellectual property, which includes clinical trials data, patient samples, patents and other assets. The Company is working towards entering into licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of the assets.
Short-term flipping only, IMO!!!
Note: My comments on companies are usually my opinion of long term success (years). The PPS may go up or down greatly in the meantime depending on the number of greedy suckers with money.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.